Search

Author/Creator Issa, Djamila E

1. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Issue 3 (March 2022)

Authors:
Kersting, Sabina; Dubois, Julie; Nasserinejad, Kazem; Dobber, Johan A; Mellink, Clemens; van der Kevie-Kersemaekers, Anne-Marie F; Evers, Ludo M; de Boer, Fransien; Koene, Harry R; Schreurs, John; van der Klift, Marjolein; Velders, Gerjo A; van der Spek, Ellen; van der Straaten, Hanneke M; Hoogen...
Journal:
Lancet
Issue:
Volume 9:Issue 3(2022)
Page Start:
e190
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search